Steve Curtis
Steve Curtis
Interim Managing Director, BrightEdge | VP, Innovation & Impact Investing | American Cancer Society
Steve Curtis is the interim managing director of BrightEdge and VP, innovation and impact investing for ACS.
Prior to joining ACS, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. He also has experience with Eli Lilly and Company, Bioscience Ventures group within 2M Companies, and Reata Pharmaceuticals.
